查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2067910

杜必康市場規模、佔有率和趨勢分析報告：按類型、分銷管道、地區和細分市場預測（2026-2033 年）

Dupixent Market Size, Share & Trends Analysis Report By Type, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

杜比森特市場概況

2025 年全球 Dupixent 市場規模估計為 152.374 億美元，預計到 2033 年將達到 275.8267 億美元。

預計從 2026 年到 2033 年，該市場將以 7.70% 的複合年成長率成長。該市場呈現強勁擴張態勢，這得益於適應症的不斷擴大以及在皮膚病學、呼吸系統醫療設備和胃腸病學領域的日益普及。

該藥物由賽諾菲和再生元共同研發，憑藉其獨特的靶向IL-4/IL-13通路的作用機制，已成為領先的生物製藥。關鍵市場法規核准的不斷推進、患者群體的擴大以及日益增強的商業性影響力，都為其成長提供了支撐。例如，2024年7月，Dupicent在歐盟獲準用於治療部分慢性阻塞性肺病（COPD）患者。這標誌著該產品在呼吸系統領域的適應症範圍顯著擴大，超越了氣喘和伴隨鼻息肉的慢性鼻竇炎等現有適應症。這項擴展反映了監管機構對該產品臨床療效的日益認可，並擴大了其在呼吸系統疾病治療領域的應用範圍。

競爭激烈的市場格局由強大的合作夥伴關係主導的創新和持續的生命週期管理策略所塑造。賽諾菲與再生元的合作關係在產品研發中繼續發揮核心作用，包括探索新的適應症和拓展兒童領域。各地區強勁的商業性表現進一步鞏固了市場發展勢頭，這得益於醫療保健系統對生物製藥在慢性發炎性疾病治療中的日益普及。關鍵市場的監管進展，包括呼吸系統和皮膚科適應症的擴展，進一步鞏固了該產品的全球地位。此外，在多個專科領域的廣泛應用提高了醫生的認知度，推動了持續的市場接受度，並鞏固了Dupixent作為免疫相關治療領域旗艦生物製藥的地位。

此外，該市場以強勁的需求成長為特徵，這得益於未滿足的醫療需求和已獲準適應症的持續擴展。慢性過敏性和呼吸系統疾病的日益普遍持續推動著全球生物製劑的使用。賽諾菲與再生元之間的策略合作進一步增強了商業化能力和全球市場覆蓋範圍。該治療方法正在拓展其臨床效用，並在多種免疫介導疾病（包括嗜伊紅性食道炎）中發揮越來越重要的治療作用。總體而言，在創新、適應症擴展以及在成熟和新興醫療保健系統中不斷提高的全球滲透率的推動下，該市場正穩步發展。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：杜比森特的市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：杜比森特市場：按類型分類的業務分析

  • 按類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按類型分類，2021-2033 年
  • 異位性皮膚炎（AD）
  • 氣喘
  • CRSwNP
  • COPD
  • 其他

第5章：杜比森特市場：按通路分類的業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 零售藥房
  • 其他

第6章：杜比森特市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第7章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Sanofi
    • Regeneron
Product Code: GVR-4-68040-657-9

Dupixent Market Summary

The global dupixent market size was estimated at USD 15,237.40 million in 2025 and is projected to reach USD 27,582.67 million by 2033, growing at a CAGR of 7.70% from 2026 to 2033. The market is witnessing strong expansion driven by continuous label extensions and rising adoption across dermatology, respiratory, and gastroenterology types.

The drug, co-developed by Sanofi and Regeneron, has established itself as a leading biologic due to its differentiated IL-4/IL-13 pathway targeting mechanism. Growth is supported by frequent regulatory advancements across major markets, expanding patient eligibility, and strengthening its commercial footprint. For instance, in July 2024, Dupixent received approval in the European Union for use in certain patients with chronic obstructive pulmonary disease (COPD), marking a notable expansion of its respiratory portfolio beyond established types such as asthma and chronic rhinosinusitis with nasal polyps. This expansion reflects increasing regulatory confidence in its clinical profile and broadens its therapeutic scope within respiratory care.

The competitive market landscape is shaped by strong collaboration-driven innovation and continuous lifecycle management strategies. The partnership between Sanofi and Regeneron remains central to ongoing product development, including exploration of additional types and pediatric expansions. Market momentum has been reinforced by strong commercial performance across regions, supported by increasing healthcare system adoption of biologics in chronic inflammatory conditions. Regulatory progress in major markets, including expansions in respiratory and dermatology segments, has further strengthened its global positioning. In addition, increasing use across multiple specialties enhances physician familiarity, driving sustained uptake and reinforcing Dupixent's position as a cornerstone biologic in immunology-related therapeutic areas.

The market is also characterized by robust demand growth supported by unmet clinical needs and ongoing expansion of approved types. The increasing prevalence of chronic allergic and respiratory conditions continues to drive biologic utilization worldwide. Strategic collaboration between Sanofi and Regeneron further strengthens commercialization capabilities and global market reach. The therapy has expanded its therapeutic relevance across multiple immune-mediated diseases, including eosinophilic esophagitis, broadening its clinical utility. Overall, the market is evolving steadily, supported by innovation, expanding types, and increasing global penetration across both established and emerging healthcare systems.

Global Dupixent Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global dupixent market report based on type, distribution channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Atopic Dermatitis (AD)
  • Asthma
  • CRSwNP
  • COPD
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Dupixent Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Patent Expiry Analysis
    • 3.3.4. Pricing Analysis

Chapter 4. Dupixent Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Atopic Dermatitis (AD)
    • 4.4.1. Atopic Dermatitis (AD) Market, 2021 - 2033 (USD Million)
  • 4.5. Asthma
    • 4.5.1. Asthma Market, 2021 - 2033 (USD Million)
  • 4.6. CRSwNP
    • 4.6.1. CRSwNP Market, 2021 - 2033 (USD Million)
  • 4.7. COPD
    • 4.7.1. COPD Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Dupixent Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2025 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Dupixent Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 6.4. North America
    • 6.4.1. North America Dupixent Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East & Africa
    • 6.8.1. Middle East & Africa Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Sanofi
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Regeneron
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global dupixent market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 5 Global dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6 North America dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 8 North America dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 U.S dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 10 U.S dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 Canada dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 12 Canada dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 Mexico dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 14 Mexico dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 Europe dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 17 Europe dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18 UK dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 19 UK dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Germany dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 21 Germany dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22 France dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 23 France dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 Italy dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 25 Italy dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26 Spain dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 27 Spain dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 Norway dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 29 Norway dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 Denmark dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 31 Denmark dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Sweden dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 33 Sweden dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 Japan dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 38 Japan dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 China dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 40 China dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41 India dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 42 India dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43 Australia dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 44 Australia dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 South Korea dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 46 South Korea dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47 Thailand dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 48 Thailand dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49 Latin America dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 51 Latin America dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Brazil dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 53 Brazil dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Argentina dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 55 Argentina dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 South Africa dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 60 South Africa dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63 UAE dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 64 UAE dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Kuwait dupixent market, by type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait dupixent market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Dupixent market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Dupixent market dynamics
  • Fig. 11 Dupixent market: Porter's five forces analysis
  • Fig. 12 Dupixent market: PESTLE analysis
  • Fig. 13 Type market, 2021 - 2033 (USD Million)
  • Fig. 14 Atopic Dermatitis (AD) market, 2021 - 2033 (USD Million)
  • Fig. 15 Asthma market, 2021 - 2033 (USD Million)
  • Fig. 16 CRSwNP market, 2021 - 2033 (USD Million)
  • Fig. 17 COPD market, 2021 - 2033 (USD Million)
  • Fig. 18 Others market, 2021 - 2033 (USD Million)
  • Fig. 19 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 20 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 21 Retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Dupixent market revenue, by region
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 North America dupixent market, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. country dynamics
  • Fig. 27 U.S. dupixent market, 2021 - 2033 (USD Million)
  • Fig. 28 Canada country dynamics
  • Fig. 29 Canada dupixent market, 2021 - 2033 (USD Million)
  • Fig. 30 Mexico country dynamics
  • Fig. 31 Mexico dupixent market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe dupixent market, 2021 - 2033 (USD Million)
  • Fig. 33 UK country dynamics
  • Fig. 34 UK dupixent market, 2021 - 2033 (USD Million)
  • Fig. 35 Germany country dynamics
  • Fig. 36 Germany dupixent market, 2021 - 2033 (USD Million)
  • Fig. 37 France country dynamics
  • Fig. 38 France dupixent market, 2021 - 2033 (USD Million)
  • Fig. 39 Italy country dynamics
  • Fig. 40 Italy dupixent market, 2021 - 2033 (USD Million)
  • Fig. 41 Spain country dynamics
  • Fig. 42 Spain dupixent market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway country dynamics
  • Fig. 44 Norway dupixent market, 2021 - 2033 (USD Million)
  • Fig. 45 Sweden country dynamics
  • Fig. 46 Sweden dupixent market, 2021 - 2033 (USD Million)
  • Fig. 47 Denmark country dynamics
  • Fig. 48 Denmark dupixent market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific dupixent market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan country dynamics
  • Fig. 51 Japan dupixent market, 2021 - 2033 (USD Million)
  • Fig. 52 China country dynamics
  • Fig. 53 China dupixent market, 2021 - 2033 (USD Million)
  • Fig. 54 India country dynamics
  • Fig. 55 India dupixent market, 2021 - 2033 (USD Million)
  • Fig. 56 Australia country dynamics
  • Fig. 57 Australia dupixent market, 2021 - 2033 (USD Million)
  • Fig. 58 South Korea country dynamics
  • Fig. 59 South Korea dupixent market, 2021 - 2033 (USD Million)
  • Fig. 60 Thailand country dynamics
  • Fig. 61 Thailand dupixent market, 2021 - 2033 (USD Million)
  • Fig. 62 Latin America dupixent market, 2021 - 2033 (USD Million)
  • Fig. 63 Brazil country dynamics
  • Fig. 64 Brazil dupixent market, 2021 - 2033 (USD Million)
  • Fig. 65 Argentina country dynamics
  • Fig. 66 Argentina dupixent market, 2021 - 2033 (USD Million)
  • Fig. 67 MEA dupixent market, 2021 - 2033 (USD Million)
  • Fig. 68 South Africa country dynamics
  • Fig. 69 South Africa dupixent market, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia country dynamics
  • Fig. 71 Saudi Arabia dupixent market, 2021 - 2033 (USD Million)
  • Fig. 72 UAE country dynamics
  • Fig. 73 UAE dupixent market, 2021 - 2033 (USD Million)
  • Fig. 74 Kuwait country dynamics
  • Fig. 75 Kuwait dupixent market, 2021 - 2033 (USD Million)
  • Fig. 76 Company categorization
  • Fig. 77 Company market position analysis
  • Fig. 78 Strategic framework